



Levana SANI
Co-founder & CEO of Nalagenetics

Levana Sani is the co-founder and CEO of Nalagenetics, a biotechnology startup that focuses on personalized healthcare through genetic testing to provide the best treatment solutions that are more affordable and safer for patients.

Levana studied biochemistry, genetics, and business and holds a Bachelor of Biochemistry from the University of Southern California followed by an MBA from Harvard Business School. While being a part of the Genome Institute of Singapore, Levana and a team of scientists founded Nalagenetics in 2016. Her contributions to Nalagenetics led to Levana being selected in the Forbes 30 under 30 in 2021.

Nalagenetics has received US\$12.6m from Series A funding and was selected as the 1st place winner in the Mobility and Healthcare categories at the 2021 G20 Innovation League. On the following year, Nalagenetics became part of Singapore's SG100K, a study to map the genome of 10,000 participants to develop better tools through precision medicine to predict and prevent chronic diseases among Singaporeans and other Asians populations.

Today, Nalagenetics' solutions are offered by a growing number of healthcare providers and laboratories in Asia and Europe, reflecting the company's exceptional standards and depth of research as a scientist-led company.